PALI

MKT CAP:$348M

Palisade Bio, Inc.

Market Cap

$348M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$2.80+$0.30 (+12.00%)

Apr 21, 2026

Company Details

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastroin...

CEO

J. D. Finley

IPO Date

Mar 30, 2007

Website

www.palisadebio.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$17M

EPS (Diluted)

-$1.48

Free Cash Flow

-$11M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

Q1 2026

May 11, 2026

PENDING

FY 2025

Mar 20, 2026

$0EPS -$0.30

Q4 2025

Mar 20, 2026

$0EPS -$0.06

Q3 2025

Nov 10, 2025

$0EPS -$0.38

Q2 2025

Aug 11, 2025

$0EPS -$0.58

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q4 21	$0	$0	-$4M
Q1 22	$0	$0	-$4M
Q2 22	$0	$0	-$4M
Q3 22	$0	$0	-$4M
Q1 23	$250.0K	$250.0K	-$3M
Q2 23	$0	$0	-$4M
Q3 23	$0	$0	-$4M
Q4 23	$0	$0	-$3M
Q1 24	$0	-$1.0K	-$4M
Q2 24	$0	$0	-$4M
Q3 24	$0	$0	-$4M
Q4 24	$0	$0	-$3M
Q1 25	$0	$0	-$2M
Q2 25	$0	$0	-$3M
Q3 25	$0	$0	-$3M
Q4 25	$0	$0	-$10M

Valuation

Quarter	P/S	P/E
Q4 21	—	—
Q1 22	—	—
Q2 22	—	12.3x
Q3 22	—	—
Q1 23	115.9x	—
Q2 23	121.4x	—
Q3 23	66.8x	—
Q4 23	97.9x	—
Q1 24	—	—
Q2 24	—	—
Q3 24	—	—
Q4 24	—	—
Q1 25	—	—
Q2 25	—	—
Q3 25	—	—
Q4 25	—	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q4 21	-$3M	-$3M
Q1 22	-$4M	-$4M
Q2 22	-$3M	-$3M
Q3 22	-$3M	-$3M
Q1 23	-$4M	-$4M
Q2 23	-$2M	-$2M
Q3 23	-$3M	-$3M
Q4 23	-$3M	-$3M
Q1 24	-$3M	-$3M
Q2 24	-$3M	-$3M
Q3 24	-$3M	-$3M
Q4 24	-$2M	-$2M
Q1 25	-$2M	-$2M
Q2 25	-$2M	-$2M
Q3 25	-$4M	-$4M
Q4 25	-$3M	-$3M

Capital Expenditures

Quarter	CapEx
Q4 21	$0
Q1 22	$0
Q2 22	$0
Q3 22	$0
Q1 23	$0
Q2 23	$4.0K
Q3 23	$0
Q4 23	$0
Q1 24	$0
Q2 24	$0
Q3 24	$0
Q4 24	$0
Q1 25	$0
Q2 25	$0
Q3 25	$0
Q4 25	$0

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q4 21	—	+24.1%
Q1 22	—	+99.0%
Q2 22	—	-89.1%
Q3 22	—	+46.3%
Q1 23	—	-31.0%
Q2 23	—	-7.2%
Q3 23	—	+5.8%
Q4 23	—	-28.5%
Q1 24	-100.0%	+32.2%
Q2 24	—	+16.7%
Q3 24	—	-4.9%
Q4 24	—	+7.2%
Q1 25	—	-37.1%
Q2 25	—	-32.5%
Q3 25	—	-18.7%
Q4 25	—	+195.1%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q4 21	$0	—
Q1 22	$358.0K	—
Q2 22	$336.0K	—
Q3 22	$252.0K	—
Q1 23	$93.0K	37.2%
Q2 23	$144.0K	—
Q3 23	$202.0K	—
Q4 23	$185.0K	—
Q1 24	$118.0K	—
Q2 24	$362.0K	—
Q3 24	$95.0K	—
Q4 24	$77.0K	—
Q1 25	$69.0K	—
Q2 25	$69.0K	—
Q3 25	$90.0K	—
Q4 25	$4M	—

OpEx Breakdown

Quarter	R&D	G&A
Q4 21	$800.0K	$3M
Q1 22	$959.0K	$3M
Q2 22	$1M	$2M
Q3 22	$2M	$2M
Q1 23	$1M	$2M
Q2 23	$2M	$1M
Q3 23	$2M	$2M
Q4 23	$1M	$2M
Q1 24	$2M	$1M
Q2 24	$3M	$2M
Q3 24	$2M	$1M
Q4 24	$2M	$1M
Q1 25	$950.0K	$1M
Q2 25	$2M	$1M
Q3 25	$1M	$2M
Q4 25	$6M	$4M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$7M	$0	$7M
Q2 22	$5M	$0	$5M
Q3 22	$14M	$0	$14M
Q4 22	$12M	$0	$12M
Q1 23	$13M	$0	$13M
Q2 23	$16M	$0	$16M
Q3 23	$15M	$0	$15M
Q4 23	$12M	$0	$12M
Q1 24	$11M	$0	$11M
Q2 24	$11M	$0	$11M
Q3 24	$8M	$0	$8M
Q4 24	$10M	$0	$10M
Q1 25	$7M	$0	$7M
Q2 25	$5M	$0	$5M
Q3 25	$5M	$0	$5M
Q4 25	$133M	$0	$133M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q4 21	271K	+11.8%	+14.0%
Q1 22	324K	+19.9%	+36.7%
Q2 22	406K	+25.1%	+3288.7%
Q3 22	65K	-84.0%	-73.2%
Q1 23	288K	+343.0%	+6.3%
Q2 23	428K	+48.7%	+31.9%
Q3 23	490K	+14.4%	+20.6%
Q4 23	9M	+1792.9%	+14170.3%
Q1 24	13M	+36.3%	+4291.0%
Q2 24	6M	-53.9%	+1259.8%
Q3 24	6M	0.0%	+1088.3%
Q4 24	9M	+46.8%	-7.9%
Q1 25	5M	-43.8%	-62.0%
Q2 25	5M	+0.0%	-17.5%
Q3 25	7M	+55.8%	+28.5%
Q4 25	56M	+644.9%	+551.9%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q4 21	$0	13
Q1 22	$0	13
Q2 22	$0	13
Q3 22	$0	13
Q1 23	$20.8K	12
Q2 23	$0	12
Q3 23	$0	12
Q4 23	$0	9
Q1 24	$0	9
Q2 24	$0	9
Q3 24	$0	9
Q4 24	$0	8
Q1 25	$0	8
Q2 25	$0	8
Q3 25	$0	8
Q4 25	$0	100K

Revenue / Employee